MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma

What is this study about? This is a medical research study testing a new drug combination ("Paclitaxel Polymer Micelles" + "Gemcitabine" + "Targeted Therapy") for patients with locally advanced unresectable or metastatic bone and soft tissue sarcomas whose disease has progressed after first-line standard therapy. Currently, there is a lack of highly effective subsequent treatment options for these patients. Why is this study being done? To improve efficacy: the investigators hope this drug combination can control tumor growth more effectively than current treatments. To reduce toxicity: The

Trial Details

NCT ID
NCT07359053
Phase
PHASE2
Sponsor
Shanghai 6th People's Hospital
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib
  • Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib
Locations (sample)
  • Shanghai, CH, China|31.22222,121.45806

Key Eligibility Criteria

  • Informed Consent: The subject has signed the informed consent form after receiving and understanding full explanation regarding the trial's purpose…
  • Target Population:
  • Histologically confirmed advanced/metastatic bone or soft tissue sarcoma. (If recurrence or metastasis is not definitive, a biopsy with frozen sect…
  • At least one measurable lesion per RECIST 1.1 criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →